Table 2.
Baseline Comparison of Subjects Who Screened Positive With Point-of-Care Testing for Metabolic Risk Criteria and Were Identified as Having Dyslipidemia, Hypertension, and Diabetesa,b
| Baseline | Subjects With Identified Conditions or Related Medications | Subjects Who Screened Positive With Point-of-Care Testing for Metabolic Risk Criteriac | Subjects Who Screened Positive and With Identified Conditions or Related Medications |
| Dyslipidemia | |||
| Total | 58.3 (70/120) | 85.8 (106/120) | 59.4 (63/106) |
| PCS | 76.7 (46/60)* | 93.3 (56/60) | 76.8 (43/56) |
| NCS | 40.0 (24/60) | 83.3 (50/60) | 40.0 (20/50) |
| Hypertension | |||
| Total | 44.2 (53/120) | 52.5 (63/120) | 84.1 (33/63) |
| PCS | 53.3 (32/60)** | 53.3 (32/60) | 62.5 (20/32) |
| NCS | 35.0 (21/60) | 51.7 (31/60) | 41.9 (13/31) |
| Diabetes | |||
| Total | 22.5 (27/120) | 22.5 (27/120) | 55.6 (15/27) |
| PCS | 26.7 (16/60) | 25.0 (15/60) | 60.0 (9/15) |
| NCS | 18.3 (11/60) | 20.0 (12/60) | 50.0 (6/12) |
Data are presented as n (%).
Total N = 120; PCS: n = 60; NCS: n = 60.
Point-of-care testing for metabolic risk criteria not at goal with identified conditions: dyslipidemia risk (total cholesterol > 200 mg/dL or LDL > 130 mg/dL or triglycerides > 150 mg/dL or men: HDL < 40 mg/dL or women: HDL < 50 mg/dL), hypertension risk (no diabetes: > 130/80 mm Hg, diabetes: > 140/85 mm Hg), and diabetes risk: (fasting = 8 h) postprandial glucose ≥ 100 mg/dL or random (1 h, 2 h, 4 h postprandial) glucose ≥ 200 mg/dL or A1c ≥ 6.5%).
P < .001.
P = .038.
Abbreviations: HDL = high-density lipoprotein, LDL = low-density lipoprotein, NCS = no pharmacist comprehensive medication management services control subject group (no point-of-care testing data were utilized to identify conditions), PCS = pharmacist comprehensive medication management services subject group (point-of-care testing data were utilized to identify conditions).